InvestorWire NewsRoom

Article

Pharmacy POC Lab Testing Growth Underscores Virtues of Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Platform, Partnerships
November 9, 2021

Pharmacy POC Lab Testing Growth Underscores Virtues of Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Platform, Partnerships

  • Pharmacy services developer Avricore Health is building its network of lab-grade testing and reporting for select conditions in an effort to make “actionable health information more accessible for everyone”
  • Avricore’s trademarked platform, HealthTab, sustains a growing trend that is counting on community pharmacists to serve their local populations by providing testing to rapidly assess medical conditions
  • The HealthTab platform is cooperative with numerous partners to create an end-to-end testing experience
  • The company aims to be in 600 locations by the end of 2023, and recently expanded its accessibility by opening five new locations in British Columbia

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is increasing access to the innovations of its walk-in pharmacy diagnostic technology thanks to the company’s expansion from key cities in Canada’s eastern locales to sites on the western seaboard, where Avricore hopes to diversify the profile of patients using its service. 

The addition of five British Columbia outlets through Avricore’s pilot partnership with nationwide pharmaceutical chain Shoppers Drug Mart is expected to serve as an early booster stage for the company’s plans to serve 600 locations by the end of 2023 (https://ibn.fm/XxX3h). Shoppers Drug Mart’s large networks includes the potential of 1,800 pharmacies across Canada, and between Canada, the U.S., and the U.K., there are opportunities for placement in about 110,000 pharmacies overall. 

Avricore’s announcement last month included news that it had completed the rollout of its point of care platform for providing lab-quality results regarding pre-diabetes. The platform is trademarked as HealthTab, a communications network that draws on data from blood samples and other fluids gathered at trademarked ID Now kiosks (Abbott Diagnostics) using the Piccolo Xpress chemistry analyzer (Abaxis Global Diagnostics). 

Avricore’s technology has the flexibility to work with an array of new partners to detect additional medical conditions from additional populations as time progresses, utilizing the professional skills of neighborhood pharmacists to oversee the process and sharing the data with the patient, the patient’s medical providers, and researchers interested in advancing science with the help of the identification-free information. 

The Pharmaceutical Journal recently noted that community pharmacies in England dispense more than 1 billion prescriptions each year, and yet a significant number of patients may suffer adverse reactions to the drugs or simply find them ineffective, which is giving rise to more service oriented approached, like testing, to establish a more personalized approach to prescriptions suited to patients’ individual capacities to benefit from them. 

“There are 11,400 community pharmacies in England that are less than a 20-minute walk from home for 89% of people,” the Journal states, citing a Pharmaceutical Services Negotiating Committee report (https://ibn.fm/In07E). “…part of the natural evolution of the role of the community pharmacist, from dispensing medicines to providing an increasing number of clinical pharmacy services. Feasibility was underlined by the fact that the service is comparable to existing community pharmacy services (e.g. the influenza vaccination service) and therefore not too onerous.”

A Pharmacy Times report earlier this year on the Pharmacy Development Services (“PDS”) 2021 conference’s discussion of point-of-care testing also cited statistics derived from a group A streptococcal (group A strep) testing program in which 278 out of 316 tested patients were found eligible to gain condition management through their pharmacy, and of that number almost half (44 percent) visited the pharmacy during hours in which a physician’s office would be closed, and 43 percent reported having no primary care provider (https://ibn.fm/Y3MaR).

“We’ve demonstrated a unique resilience by remaining focused on our goal of creating the world’s largest rapid testing network in pharmacy,” Avricore Health CEO Hector Bremner stated in a June news release (https://ibn.fm/x303p). “We are well on our way to making actionable health information more accessible for everyone and dramatically expanding our network in the coming months.”

For more information, visit the company’s website at www.AvricoreHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).